Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
Antineoplastic Agents Immunologic Factors Antirheumatic Agents Immunosuppressive Agents Monoclonal antibodies Antineoplastic and Immunomodulating Agents
Rituximab 100 MG
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production
0.8 hours (mammalian reticulocytes, in vitro)
Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help. Low blood pressure. Feeling tired or weak. Chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu. Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing. Headache. Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. Belly pain. Loose stools (diarrhea). Cough. Runny nose. Swelling in the arms or legs. Low white blood cell count or low platelet count. High blood pressure. Brain infection may rarely happen.